

Simple, Visual, Point-of-Care SARS-CoV-2 Detection Incorporating Recombinase Polymerase Amplification and Target DNA–Protein Crosslinking Enhanced Chemiluminescence

CONTENTS

Table S1. Detailed information of the oligonucleotide sequences used in this study.	S2
Figure S1. The designed SARS-CoV-2 N gene plasmid map.....	S3
Figure S2. Effect of the PIP enhancer on RPADPCL chemiluminescent signal strength	S4
Figure S3. Identification of SARS-CoV-2 N gene plasmid by 1% agarose gel electrophoresis.	S5
Figure S4. Identification of RPA products for SARS-CoV-2 N gene plasmid detection by 1% agarose gel electrophoresis.....	S5
Figure S5. Identification of SARS-CoV-2 IVT RNA by 1% agarose gel electrophoresis.	S5
Figure S6. Identification of RPA products for IVT RNA detection by 1% agarose gel electrophoresis.	S6
Table S2. Comparison between the proposed method and other RPA-based SARS-CoV-2 detection methods.	S7
Reference	S8

Table S1. Detailed information of the oligonucleotide sequences used in this study.

Names	Sequences (5'-3')
SARS-CoV-2 N gene	ATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGA CCCTCAGATTCAACTGGCAGTAACCAGAATGGAGAACGCAGTGGGGCGCGATCAAA ACAACGTCGGCCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACCGCTCTCAC TCAACATGGCAAGGAAGACCTTAAATTCCTCGAGGACAAGGCGTTCCAATTAACA CCAATAGCAGTCCAGATGACCAAATTGGCTACTACCGAAGAGCTACCAGACGAATT CGTGGTGGTGACGGTAAAATGAAAGATCTCAGTCCAAGATGGTATTTCTACTACCTA GGAAGTGGGCCAGAAGCTGGACTTCCCTATGGTGCTAACAAAGACGGCATCATATG GGTTGCAACTGAGGGAGCCTTGAATACACCAAAGATCACATTGGCACCCGCAATC CTGCTAACAAATGCTGCAATCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAG GCTTCTACGCAGAAGGGAGCAGAGGCGGCAGTCAAGCCTCTTCTCGTTCCTCATCAC GTAGTCGCAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAAGTTCTCCT GCTAGAATGGCTGGCAATGGCGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGA TTGAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAAACAAGGCCAAAC TGTCACTAAGAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGCAAAAACGTACTGC CACTAAAGCATACAATGTAACACAAGCTTTCGGCAGACGTGGTCCAGAACAAACCC AAGGAAATTTGGGGACCAGGAAGTAATCAGACAAGGAAGTATTACAAACATTGG CCGCAAATTGCACAATTTGCCCCAGCGCTTCAGCGTTCTTCGGAATGTCGCGCATT GGCATGGAAGTCACACCTTCGGGAACGTGGTTGACCTACACAGGTGCCATCAAATT GGATGACAAAGATCCAAATTTCAAAGATCAAGTCATTTTGCTGAATAAGCATATTGA CGCATACAAAACATTCCCACCAACAGAGCCTAAAAAGGACAAAAAGAAGAAGGCT GATGAAACTCAAGCCTTACCGCAGAGACAGAAGAAACAGCAAAGTGTGACTCTTCT TCCTGCTGCAGATTGATGATTCTCCAAACAATTGCAACAATCCATGAGCAGTGC TGACTCAACTCAGGCCTAA
SARS-2 FP	CAACTTCCTCAAGGAACAACATTGCCAAAA
SARS-2 RP	TGGAGTTGAATTTCTTGAAGTGTGCGACT
SARS-2 FP-biotin	biotin-CAACTTCCTCAAGGAACAACATTGCCAAAA
SARS-2 RP-biotin	biotin-TGGAGTTGAATTTCTTGAAGTGTGCGACT




Figure S1. The designed SARS-CoV-2 N gene plasmid map.




Figure S2. Effect of the PIP enhancer on RPADPCL chemiluminescent signal strength.




Figure S3. Identification of SARS-CoV-2 N gene plasmid by 1% agarose gel electrophoresis. M: DNA marker; Lane 1: The designed SARS-CoV-2 N gene plasmid. Lane 2: The plasmid after *AscI* enzyme digestion.




Figure S4. Identification of RPA products for SARS-CoV-2 N gene plasmid detection by 1% agarose gel electrophoresis. M: DNA marker; Lane 1: negative control; Lane 2-9: The concentration of SARS-CoV-2 N gene plasmid was 1000, 500, 300, 200, 100, 50, 10, 1 copies, respectively.




Figure S5. Identification of SARS-CoV-2 IVT RNA by 1% agarose gel electrophoresis. M: DNA marker; Lane 1: The IVT RNA synthesized by RiboMAX Large Scale RNA Production System Kit. Lane 2: The IVT RNA synthesized by T7 Quick High Yield RNA Transcription Kit.




Figure S6. Identification of RPA products for IVT RNA detection by 1% agarose gel electrophoresis.

M: DNA marker; Lane 1: negative control; Lane 2-10: The concentration of SARS-CoV-2 N gene plasmid was 2000, 1000, 500, 300, 200, 100, 50, 10, 1 copies, respectively.

Table S2. Comparison between the proposed method and other RPA-based SARS-CoV-2 detection methods.

No.	Methods	Target genes	Sensitivity (LOD)	Quantification	Visualization	Detection time	Ref.
1	Strip	N/ORF1ab gene	10 copies	×	√	60 min	[1]
2	CRISPR/Cas9-mediated strip	E/ORF1ab gene	100 copies	×	√	58 min	[2]
3	Strip	N/S gene	10 copies	×	√	45 min	[3]
4	Microfluidic-integrated strip	N gene	30 copies	×	√	20 min	[4]
5	Strip	N gene	35.4 copies	×	√	45 min	[5]
6	CRISPR/Cas fluorometry	N/ORF1ab gene	2 copies	√	×	50 min	[6]
7	Colorimetric CRISPR/Cas12a assay	N/ORF1ab gene	1 copy	√	×	240 min	[7]
8	Real-time RPA	N gene	10 copies	√	×	27 min	[8]
9	Real-time RPA	ORF1ab/S gene	10 copies	√	×	24 min	[9]
10	Real-time RPA	N/E/RdRP gene	15 copies	√	×	15 min	[10]
11	Fluorescent strip	E/RdRP gene	9.5 copies	√	×	30 min	[11]
12	CRISPR/Cas-based lab-on- paper	N/S gene	100 copies	√	×	60 min	[12]
13	Chemiluminometry	N gene	15 copies	√	√	60 min	This work

Reference

1. Sun, Y.; Qin, P.; He, J.; Li, W.; Shi, Y.; Xu, J.; Wu, Q.; Chen, Q.; Li, W.; Wang, X., Rapid and simultaneous visual screening of SARS-CoV-2 and influenza viruses with customized isothermal amplification integrated lateral flow strip. *Biosens. Bioelectron.* **2022**, 197, 113771.
2. Xiong, E.; Jiang, L.; Tian, T.; Hu, M.; Yue, H.; Huang, M.; Lin, W.; Jiang, Y.; Zhu, D.; Zhou, X., Simultaneous dual-gene diagnosis of SARS-CoV-2 based on CRISPR/Cas9-mediated lateral flow assay. *Angew. Chem. Int. Edit.* **2021**, 60, (10), 5307-5315.
3. Qian, J.; Boswell, S. A.; Chidley, C.; Lu, Z.-x.; Pettit, M. E.; Gaudio, B. L.; Fajnzylber, J. M.; Ingram, R. T.; Ward, R. H.; Li, J. Z., An enhanced isothermal amplification assay for viral detection. *Nat. Commun.* **2020**, 11, (1), 5920.
4. Liu, D.; Shen, H.; Zhang, Y.; Shen, D.; Zhu, M.; Song, Y.; Zhu, Z.; Yang, C., A microfluidic-integrated lateral flow recombinase polymerase amplification (MI-IF-RPA) assay for rapid COVID-19 detection. *Lab Chip* **2021**, 21, (10), 2019-2026.
5. Shelite, T. R.; Uscanga-Palomeque, A. C.; Castellanos-Gonzalez, A.; Melby, P. C.; Travi, B. L., Isothermal recombinase polymerase amplification-lateral flow detection of SARS-CoV-2, the etiological agent of COVID-19. *J. Virol. Methods* **2021**, 296, 114227.
6. Huang, Z.; Tian, D.; Liu, Y.; Lin, Z.; Lyon, C. J.; Lai, W.; Fusco, D.; Drouin, A.; Yin, X.; Hu, T., Ultra-sensitive and high-throughput CRISPR-powered COVID-19 diagnosis. *Biosens. Bioelectron.* **2020**, 164, 112316.
7. Zhang, W. S.; Pan, J.; Li, F.; Zhu, M.; Xu, M.; Zhu, H.; Yu, Y.; Su, G., Reverse transcription recombinase polymerase amplification coupled with CRISPR-Cas12a for facile and highly sensitive colorimetric SARS-CoV-2 detection. *Anal. Chem.* **2021**, 93, (8), 4126-4133.
8. Wu, T.; Ge, Y.; Zhao, K.; Zhu, X.; Chen, Y.; Wu, B.; Zhu, F.; Zhu, B.; Cui, L., A reverse-transcription recombinase-aided amplification assay for the rapid detection of N gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Virology* **2020**, 549, 1-4.
9. Xue, G.; Li, S.; Zhang, W.; Du, B.; Cui, J.; Yan, C.; Huang, L.; Chen, L.; Zhao, L.; Sun, Y., Reverse-transcription recombinase-aided amplification assay for rapid detection of the 2019 novel coronavirus (SARS-CoV-2). *Anal. Chem.* **2020**, 92, (14), 9699-9705.
10. El Wahed, A. A.; Patel, P.; Maier, M.; Pietsch, C.; Rüster, D.; Böhlken-Fascher, S.; Kissenkötter,

- J.; Behrmann, O.; Frimpong, M.; Diagne, M. M., Suitcase lab for rapid detection of SARS-CoV-2 based on recombinase polymerase amplification assay. *Anal. Chem.* **2021**, 93, (4), 2627-2634.
11. Cherkaoui, D.; Huang, D.; Miller, B. S.; Turbé, V.; McKendry, R. A., Harnessing recombinase polymerase amplification for rapid multi-gene detection of SARS-CoV-2 in resource-limited settings. *Biosens. Bioelectron.* **2021**, 189, 113328.
12. Yin, K.; Ding, X.; Li, Z.; Sfeir, M. M.; Ballesteros, E.; Liu, C., Autonomous lab-on-paper for multiplexed, CRISPR-based diagnostics of SARS-CoV-2. *Lab Chip* **2021**, 21, (14), 2730-2737.